Pfizer made one thing clear this week: It's officially back in the obesity race.

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with ...

A team of scientists has uncovered a critical mechanism that could pave the way for safer and more effective obesity ...

Over the next decade, obesity rates across the nation could surge to close to half of U.S. adults, a new study published in ...

Researchers have quantified the role of obesity in common long-term conditions, showing for the first time the effect of ...

Corbus Pharmaceuticals maintains a 'Hold' rating as it advances CRB-701 for HNSCC and CRB-913 for obesity. Click here to read ...

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is ...

Biopharma’s obsession with the weight loss sector—projected to exceed $130 billion in revenue by 2035—shows no signs of ...

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

Obesity is contributing to a record proportion of deaths among pregnant women, the Royal College of Physicians has warned.

Sen. Ana Maria Rodriguez and Rep. Susan L. Valdés were joined Thursday by Dr. Joey Jarrard of Tallahassee Memorial Healthcare ...